Specialized cell & gene therapy clinical development
Cell and gene therapies (CAGT) represent a groundbreaking force in medicine and research. These cell-based and novel gene therapies have the potential to cure a disease. It is this potential of eliminating disease that makes them so revolutionary. For the researchers and developers of these innovative therapies, continuous pursuit to improve the quality of human lives remains at the core of every clinical development decision made toward advancing CAGT therapeutic options.
Developing successful cell and gene therapy clinical trials is a complex process due to many operational challenges and regulatory scrutiny. As biotech companies embark on clinical trial planning and execution, it is critical to find a CRO delivery partner to help anticipate and navigate these operational complexities that arise when designing and running clinical trials for cell and gene therapies.
CAGT Study Management Team
Answering the call for innovation to address specific challenges of cell and gene therapy drug development, we have formed a multidisciplinary Cell and Gene Therapy Study Management team. This comprehensive unit is designed for CAGT-focused biotech partners, integrating the IQVIA Biotech clinical program strategy and delivery with the IQVIA Cell and Gene Therapy Center of Excellence. Together, these groups form your CAGT Study Management team, dedicated to an end-to-end, seamless experience for biotech customers.
Aligned CAGT Strategy and Delivery
We believe that having our CAGT operational delivery as a streamlined process is at the heart of your program’s success. Because of this, we design your delivery strategy with the following core principles:
- Seamless CAGT solutions applied throughout the study process
- Dedicated CAGT-expert cross-functional delivery teams
- Medical expertise across all therapeutic areas
- Clinical trial design, delivery and logistics support
- Optimized communication to efficiently achieve trial milestones
- Integrate lessons learned and experiences into innovation and value for patients
- Supported 80+ full-service CAGT clinical trials for biotech sponsors in the past 10 years
- More than 70% of Project Managers have 3+ years of CAGT experience
- 100% dedicated to biotech customers
Navigating Operational Complexities
Our Latest Thinking
Cell & Gene Therapy COE
Drive cell and gene therapy development from candidate identification through market authorization.
Drive smarter decisions with IQVIA Connected Intelligence
Our powerful approach brings together CAGT experts, data-driven insights, global site networks, and innovative technologies to help you drive smarter decisions to accelerate CAGT clinical development.
Generate and disseminate the right real world evidence (RWE) to meet stakeholder needs with confidence.
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are.
Access new resources for advanced therapy development, from candidate identification through market authorization.